All News
Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
Dr. Rachel Tate uptoTate ( View Tweet)
Enjoy the post-session adult beverage #ACR22 and #rheumtwitter but, choose wisely as Abs 1206 finds beer consumption was consistently assoc'd w/ higher serum urate levels, whereas sake showed only modest associations in both males and females. @RheumNow https://t.co/ETtU31iTZ0 https://t.co/keG5IN7LbC
Dr. Rachel Tate uptoTate ( View Tweet)
Catch our daily recap LIVE at 5pm ET. #ACR22 https://t.co/OpPcGhnWJ1
Dr. John Cush RheumNow ( View Tweet)
Dr. @Drbeckyg reminds us that self-reported, RA patient completed joint counts are good for tender and ok for swollen. Check out her videos for teaching joint counts to your patients - all under 8 minutes in total. #ACR22 @RheumNow https://t.co/E2wBsNFS12
Dr. Rachel Tate uptoTate ( View Tweet)
Makol @AshimaMakol et al. Digital ischaemia 79% SSc patients. Higher risk - digital occlusive arterial disease on laser doppler flowmetry Macrovascular disease on US, ILD, calcinosis, pericardial effusion. @RheumNow #ACR22 Abstr#1518 https://t.co/DJTtCVD0Oe https://t.co/9i4Vivir8q
Richard Conway RichardPAConway ( View Tweet)
Chen et al. Tofacitinib in new-onset PMR. Tofa (No GC!) vs standard GC. Equally effective! @RheumNow #ACR22 Abstr#1107 #ACRbest https://t.co/w3WJ8YZsyz https://t.co/qmt1RUAAGB
Richard Conway RichardPAConway ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
"Telemedicine is not inferior to F2F visits in Rheumatology!" Dr. @RheumNow. While this may be true, it takes patient education and setting expectations about the visit (no driving during appointment!) #ACR22 @KDAO2011
Dr. Rachel Tate uptoTate ( View Tweet)
Torgutalp et al. Higher NSAID intake associated reduced spinal progression in AxSpA esp. r-AxSpA. Cox-2 may have greater effect than other NSAIDs. @RheumNow #ACR22 Abstr#1492 https://t.co/bGH6bBo7AD https://t.co/XBFV410Y2p
Richard Conway RichardPAConway ( View Tweet)
Baker et al, Corevitas registry in 7000+ RA pts
Pts w/ moderate pain HR 1.37
Pts w/ severe pain HR 1.42
more likely to switch to diff MOA b/tsDMARD
Adjusted for confounders incl DA
Time we address pain separately to spare MAOs in a lifelong disease!
Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m
Aurelie Najm AurelieRheumo ( View Tweet)
Joerns et al. Baseline IL-17 higher in RD-ILD vs IPF. Low IL-13 assoc shorter progression free survival HR 17.36 @RheumNow #ACR22 Abstr#1109 https://t.co/I8R3SrxNfV https://t.co/he1A3SYDp0
Richard Conway RichardPAConway ( View Tweet)
Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Richard Conway RichardPAConway ( View Tweet)
"Tweeting a conference is hard work!" @rheum_cat is right! Shout out to all of the #rheumtwitter, RN reporters, conference attendees and all of those tweeting from home! #ACR22 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Avouac @AvouacJerome et al. Maintaining complete B cell depletion assoc RTX efficacy in CTD-ILD. % with FVC improvement - 67% vs 50% for B cell depletion 1 year, 89% vs 50% B cell depletion last infusion. @RheumNow #ACR22 Abstr#1527 https://t.co/xr7DHOHci2 https://t.co/2n95PgzLxN
Richard Conway RichardPAConway ( View Tweet)
Reid et al. Emphysema, lymphadenopathy, consolidative opacities on CT pre-ICI increase risk of ICI pneumonitis. Pul nodules decrease risk. GERD, asthma in history also increase risk. @RheumNow #ACR22 Abstr#1108 https://t.co/ZD8ibsECnV https://t.co/FVnQgn2I2S
Richard Conway RichardPAConway ( View Tweet)
Day 1 Report
The masses have returned to #ACR22, a hybrid meeting that began Saturday in Philadelphia. Throngs and gaggles of MSK wannabees crammed the ballrooms and rushed the exhibits as they relived the rheumatologic meeting we once knew.
https://t.co/8GjRAT7Zuy https://t.co/vyXRcVxOpo
Links:
Dr. John Cush RheumNow ( View Tweet)
In RA after first-line TNFi, improvements in disease activity & PROs were seen with 2nd line ETN and JAKi. Some measures had greater improvement in JAKi group. Some patients can benefit from TNF cycling. Pappas D CorEvitas Abs1588 https://t.co/cHW5tm97kx #ACR22 @RheumNow https://t.co/bx0p04AQzd
Dr. Antoni Chan synovialjoints ( View Tweet)
Abs 1559 at #ACR22 long-term efficacy of apremilast differs between oral and genital ulcers, skin lesions and joint lesions. There may be differences in the long-term efficacy of apremilast dependent on manifestation type. @RheumNow https://t.co/I8p5fd1CA1 https://t.co/XKjpIUeiah
Dr. Rachel Tate uptoTate ( View Tweet)
In this study by Stoots et al, #lupus pts w/ ⬇️ CV risk (accdg to ASCVD risk calc) had significantly abn. CAC vs. controls and assoc with:
🦋Older age, ⬇️GFR, ⬆️TC&LDL, longer dse duration.
More data needed but consider regular CV screens in these pts
#ACR22 @RheumNow ABST#1596 https://t.co/pECZw1n6lb
sheila RHEUMarampa ( View Tweet)
What should you use as a second-line biologic in PsA patients?
In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi.
Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we
Robert B Chao, MD doctorRBC ( View Tweet)